Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.

Pattanaik S, Malhotra S, Sharma YP, Pandhi P.

J Cardiovasc Pharmacol. 2012 May;59(5):479-84. doi: 10.1097/FJC.0b013e31824ba699.

PMID:
22569288
2.

Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.

Rifaie O, Zahran A, Nammas W.

Anadolu Kardiyol Derg. 2012 Mar;12(2):90-6. doi: 10.5152/akd.2012.032. Epub 2012 Jan 26.

3.
4.

Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.

Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.

Clin Ther. 2007 Nov;29(11):2365-73.

PMID:
18158077
5.

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M; DISCOVERY PENTA investigators.

Curr Med Res Opin. 2005 Aug;21(8):1307-15.

PMID:
16083541
6.

Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.

Ferrer-García JC, Pérez-Silvestre J, Martínez-Mir I, Herrera-Ballester A.

Acta Diabetol. 2006 Nov;43(3):75-8.

PMID:
17143784
7.
8.

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).

Smith DG, McBurney CR.

Pharmacoeconomics. 2003;21 Suppl 1:13-23.

PMID:
12648031
9.
10.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group.

Am J Cardiol. 2003 Jul 15;92(2):152-60.

PMID:
12860216
11.

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.

Andrews TC, Ballantyne CM, Hsia JA, Kramer JH.

Am J Med. 2001 Aug 15;111(3):185-91.

PMID:
11530028
12.

Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.

Bullano MF, Kamat S, Wertz DA, Borok GM, Gandhi SK, McDonough KL, Willey VJ.

Am J Health Syst Pharm. 2007 Feb 1;64(3):276-84.

PMID:
17244877
13.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
14.

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.

Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG.

Am J Cardiol. 2003 Mar 6;91(5A):11C-17C; discussion 17C-19C.

PMID:
12646338
15.

Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.

Sansanayudh N, Wongwiwatthananukit S, Putwai P, Dhumma-Upakorn R.

Ann Pharmacother. 2010 Mar;44(3):415-23. doi: 10.1345/aph.1M522. Epub 2010 Feb 23.

PMID:
20179259
16.

The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.

Lam HC, Chu CH, Wei MC, Keng HM, Lu CC, Sun CC, Lee JK, Chuang MJ, Wang MC, Tai MH.

Exp Biol Med (Maywood). 2006 Jun;231(6):1010-5.

PMID:
16741040
17.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
18.

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.

Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group.

Am Heart J. 2004 Sep;148(3):447-55.

PMID:
15389231
19.

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.

Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.

Am Heart J. 2006 May;151(5):975.e1-9.

PMID:
16644314
20.

Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.

Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.

Indian Heart J. 2008 May-Jun;60(3):215-22.

PMID:
19240310

Supplemental Content

Support Center